Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, and to assess overall survival. The secondary objectives are to assess progression free survival, and to assess the T cell clonality, CD8 T cell activation and Tumor Infiltrating Lymphocyte (TIL) score after treatment
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony glejak wielopostaciowy (WHO stopień IV)
- •Nawrót guza mózgu z zaplanowaną operacją i ponowną radioterapią
- •Rozmiar guza mniejszy niż 6 cm
- •Dobry stan ogólny pacjenta (ECOG 0-1)
- •Prawidłowe wyniki badań laboratoryjnych
✗ Disqualifies
- •Przeciwwskazania do dodatkowej radioterapii
- •Wcześniejsze leczenie pembrolizumabem lub podobnymi lekami immunologicznymi
- •Zaburzenia odporności lub przewlekłe stosowanie sterydów
- •Ciężka uczulenie na pembrolizumab
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Cedars-Sinai Medical Center
Los Angeles, United States
Trial contact
Clinical Trial Recruitment Navigator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.